In addition, intravenous delivery of mesenchymal stem cells (MSCs) overexpressing CXCR4 improves cardiac function and remodeling after MI, suggesting CXCR4 as an important therapeutic target for the treatment of cardiovascular diseases [10]. This evidence concerns the gene CXCR4 and myocardial infarction.